Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 April 2000Website:
http://www.exelixis.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 21:34:41 GMTDividend
Analysts recommendations
Institutional Ownership
EXEL Latest News
Billionaire Jim Simons' hedge fund holds a strong interest in Novo Nordisk and Exelixis. Novo Nordisk is known for its extensive portfolio and research in diabetes and obesity.
Examine Exelixis' (EXEL) international revenue results and their impact on financial analysts' forecasts on Wall Street, as well as the stock's future potential.
Exelixis (EXEL) reports lower than expected earnings and sales for the first quarter, causing its shares to decline in response.
While the revenue and EPS of Exelixis (EXEL) provide insight into its performance in the quarter ending March 2024, it could be beneficial to also assess how certain important metrics stack up against Wall Street predictions and the figures from the same period last year.
Investors interested in Medical - Biomedical and Genetics stocks may be familiar with both Exelixis (EXEL) and Regeneron (REGN). However, the question remains: which of these stocks is more appealing to value investors?
Investors focusing on Medical - Biomedical and Genetics stocks are probably acquainted with Exelixis (EXEL) and Regeneron (REGN). However, which of these two stocks offers a more advantageous value opportunity at present?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
Exelixis Inc. (EXEL, Financial) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to treat patients with various types of cancer.
The heavy selling pressure might have exhausted for Exelixis (EXEL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Exelixis (EXEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What type of business is Exelixis?
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
What sector is Exelixis in?
Exelixis is in the Healthcare sector
What industry is Exelixis in?
Exelixis is in the Biotechnology industry
What country is Exelixis from?
Exelixis is headquartered in United States
When did Exelixis go public?
Exelixis initial public offering (IPO) was on 17 April 2000
What is Exelixis website?
https://www.exelixis.com
Is Exelixis in the S&P 500?
No, Exelixis is not included in the S&P 500 index
Is Exelixis in the NASDAQ 100?
No, Exelixis is not included in the NASDAQ 100 index
Is Exelixis in the Dow Jones?
No, Exelixis is not included in the Dow Jones index
When does Exelixis report earnings?
The next expected earnings date for Exelixis is 01 August 2024